Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06148181 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

A Phase 1 study, sponsored by AbbVie.

Completed
Registry status
Phase 1
Development phase
41
Enrollment target

NCT06148181: Completed Phase 1 study, sponsored by AbbVie.

NCT06148181 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06148181, a Phase 1 study, has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 1
Development phase
41 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.

Primary Outcome

Cmax of ABBV-141 will be assessed.

Interventions

  • DRUG ABBV-141
  • DRUG Placebo for ABBV-141

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2024-01-29
Est. Completion 2024-12-30
Phase Phase 1
AbbVie

526 total trials

What the finished NCT06148181 record still lists

NCT06148181 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).

The record links to 0 conditions, and to 2 interventions - of which ABBV-141 is the first listed.

NCT06148181 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06148181 about?

NCT06148181 is a clinical study titled "A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants". The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.

What is the current status of trial NCT06148181?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2024-01-29. Estimated completion is 2024-12-30.

What interventions are being tested in trial NCT06148181?

The interventions under investigation include: ABBV-141 (DRUG), Placebo for ABBV-141 (DRUG).

Who is sponsoring clinical trial NCT06148181?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06148181's enrollment target sits among peer trials

41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06148181, the US trial registry maintained by the National Library of Medicine. NCT06148181 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.